Pope Francis Injures His Arm After A Fall: Know How To Prevent Falls

Updated Jan 20, 2025 | 11:33 AM IST

SummaryPope Francis' subsequent injuries highlight the need for skeletal health care among the elderly. Measures include adequate calcium and vitamin D intake, regular weight-bearing exercises, and fall prevention strategies.
Pope Francis

Pope Francis (Credit: X)

Pope Francis injured his right arm after suffering a fall earlier this week. According to the Vatican, while the 88-year-old pontiff did not break his arm, a sling was put on as a precaution. This incident comes just weeks after another fall on December 7, where he hit his chin on a nightstand, resulting in another, visible bruise. The pope's health has been a topic of ongoing speculation due to his age and medical history, which includes long bouts of bronchitis and mobility challenges. Often seen using a wheelchair or a cane, Francis also uses a walker within the Vatican's Santa Marta hotel, where he resides. Notably, his frailty has brought renewed attention to the risks of falls among elderly individuals and the steps one must follow to mitigate such falls.

Preventive Measures For Bone Health

A study published in Frontiers in Aging Neurosciences people get older, the bone density in the lower back and thigh bone decreases significantly. This raises the risk of osteoporosis (OP). Therefore it becomes pivotal to pay early attention to nutrition, exercise ability, vitamin D levels, and uric acid levels in older individuals to prevent Ostreopsis and mitigate fall risks. The risk of falls and bone injuries among elderly individuals underscores the importance of preventive measures for maintaining bone health and minimizing fall risks.

Elderly, particularly menopausal women, require a daily calcium intake of 1,200 mg, divided into two or more doses. This can be achieved through dietary sources such as dairy and non-dairy products or through supplements like calcium carbonate and calcium citrate. However, total daily calcium intake should not exceed 2,500 mg to avoid potential health risks.

Vitamin D is essential for calcium absorption and bone mineralization. While sunlight exposure helps synthesize vitamin D, older individuals often require supplements due to reduced skin synthesis and the limited availability of foods. Fortified milk and supplements containing 200–600 IU of vitamin D daily are recommended, with higher doses required for those with deficiencies. Severe cases may necessitate high-dose treatments, such as 50,000 IU weekly for up to three months, along with regular monitoring of calcium and vitamin D levels.

Regular exercise is vital for preserving bone mass and reducing fall risk. Weight-bearing activities, strength training, and balance exercises like brisk walking or skipping can enhance bone density and improve coordination. Experts recommend at least 30 minutes of moderate physical activity most days of the week, supplemented by strength training twice weekly. For individuals unable to engage in standard exercise routines, alternatives like vibrating platforms may help maintain bone health.

Falls remain a leading cause of fractures among individuals over 60. Addressing contributing factors such as balance issues, vision problems, and environmental hazards can significantly reduce risks. Preventive measures include regular vision checks, minimizing medications causing dizziness, improving home safety (e.g., installing railings and removing loose rugs), and wearing rubber-soled footwear. Hip protectors may also help mitigate the impact of falls.

End of Article

Mounjaro Becomes India’s Top-Selling Medicine in October; What’s Driving The Surge

Updated Nov 8, 2025 | 12:01 PM IST

SummaryEli Lilly’s weight-loss and diabetes drug Mounjaro became India’s top-selling medicine by value in October, surpassing GSK’s Augmentin, according to data from Pharmarack. The injectable, launched in March 2025, brought in ₹1 billion in sales as demand for GLP-1 drugs soars.
mounjaro india medicine

Credits: Canva

Eli Lilly’s weight-loss and diabetes injection, Mounjaro, has overtaken GSK’s antibiotic Augmentin (GSK.L) to become India’s highest-selling drug by value in October, as demand for weight-loss treatments continues to surge in the world’s most populated country. According to new data from research firm Pharmarack, the U.S.-based drugmaker’s popular injectable earned ₹1 billion ($11.38 million) in sales last month, compared to Augmentin’s ₹800 million.

While Augmentin still led in overall units sold—5.8 million doses versus 85,000 of Mounjaro—the latter’s premium pricing pushed it ahead in total value, as per Reuters. Analysts say India is rapidly emerging as a major market for obesity treatments, with the global weight-loss drug sector expected to cross $150 billion annually by the end of this decade.

Eli Lilly’s Mounjaro Becomes India’s Top-Selling Medicine in October

Launched in India in March 2025, Mounjaro which helps regulate blood sugar levels and reduces appetite—has seen its sales double within months, surpassing its rival Wegovy by Novo Nordisk, which entered the Indian market in June. Data from Pharmarack shows that Mounjaro has so far generated ₹3.33 billion in total revenue.

“Mounjaro’s consumption in India by volume was nearly ten times higher than Wegovy in October,” said Sheetal Sapale, Vice President (Commercial) at Pharmarack. Eli Lilly sold around 262,000 doses of Mounjaro last month, compared to 26,000 doses of Wegovy. Both drugs belong to the GLP-1 receptor agonist class, designed to treat obesity and type 2 diabetes.

How Does Mounjaro Work?

Mounjaro is a once-weekly injectable medication developed primarily for managing type 2 diabetes. Its key ingredient, tirzepatide, is the first of its kind to act on two gut hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism makes Mounjaro more advanced than older drugs such as Ozempic (semaglutide) or Victoza (liraglutide), which target only GLP-1, which is thus driving a surge in its sale in india.

Although it was originally approved for diabetes management, Mounjaro has attracted global attention for its strong weight-loss effects. Ongoing studies are evaluating its use for non-diabetic individuals struggling with obesity. The drug mimics the action of GIP and GLP-1, which are hormones released naturally after meals to regulate insulin release, lower blood sugar, and suppress appetite.

Mounjaro for Type 2 Diabetes

For people living with type 2 diabetes, keeping blood sugar in check often requires a combination of medicines, diet adjustments, and regular monitoring. Mounjaro offers a more integrated solution by targeting multiple factors that influence glucose levels. Findings from clinical trials, including the SURPASS-1 to SURPASS-5 studies, show that Mounjaro delivers better outcomes than many existing diabetes treatments, particularly in lowering HbA1c levels—a key marker of long-term glucose control.

Patients using Mounjaro have shown:

  • Lower fasting and post-meal blood sugar levels
  • Reductions in HbA1c by up to 2.5%
  • Improved insulin sensitivity

Mounjaro and Weight Loss

Beyond its use for diabetes, Mounjaro has gained global popularity for its significant role in weight reduction. Clinical studies reveal that people taking the drug often lose between 15% and 20% of their body weight over several months of consistent use. This level of weight loss surpasses that seen with many earlier treatments and even some surgical interventions, making Mounjaro one of the most effective options currently available for managing obesity.

Disclaimer: This article is intended for general information and should not replace professional medical guidance. Always consult your doctor for advice or concerns regarding any health condition.

End of Article

Trump Administration May Deny Visas To Obese, Diabetic Immigrants: What We Know So Far

Updated Nov 8, 2025 | 10:23 AM IST

SummaryThe Trump administration is reportedly considering new visa rules that could deny entry to immigrants with health conditions like obesity or diabetes. According to KFF Health News, a State Department cable instructed visa officers to assess applicants based on medical history, financial ability, and even the health of family members.
donald trump mri scan

Credits: CANVA

Following the sharp hike in the H-1B visa fee to $100,000, the Trump administration may soon begin rejecting visa applications from foreigners with certain health conditions, including diabetes and obesity.

While there has been no formal confirmation from U.S. authorities, a report by KFF Health News said a cable from the State Department to embassies and consulates listed new health-related grounds for visa denials.

Trump May Now Deny Entry to Diabetic and Obese Immigrants

According to the report, the guidance instructs visa officers to consider applicants ineligible for entry based on factors such as age and medical conditions, including cardiovascular and respiratory diseases, cancer, diabetes, metabolic and neurological disorders, and certain mental health conditions.

Officers have also been told to evaluate other issues such as obesity — which can contribute to high blood pressure, asthma, and sleep apnea, when assessing whether an applicant might become a “public charge,” or a potential financial burden on the U.S. government.

The guidance further directs officials to determine whether the applicant has sufficient financial resources to pay for their care. “Does the applicant have adequate financial resources to cover the costs of such care over his entire expected lifespan without seeking public cash assistance or long-term institutionalization at government expense?” the cable states.

It adds that individuals who could become a “public charge” — due to age or chronic health problems, may be denied entry for potentially relying on U.S. public resources.

Although the directive applies broadly to most visa categories, it is expected to primarily impact those applying for permanent residency, senior attorney Charles Wheeler told KFF Health News.

Can US Officers Reject Visas Over Health Or Financial Ability?

Visa officers have also been instructed to evaluate whether applicants can afford medical treatment independently, without relying on U.S. public funds.

Wheeler said the new rule gives officers the power to form their own opinions on what might lead to future medical emergencies or financial strain. “That’s concerning because these officers are not medically trained, have no expertise in this area, and should not be making projections based on personal judgment or bias,” Wheeler said.

US Visa Officers To Consider Health Of Applicants’ Family Members

The cable also instructs visa officers to assess the health of applicants’ family members — including children or elderly parents, when determining visa eligibility.

“Do any of the dependents have disabilities, chronic medical conditions, or other special needs and require care such that the applicant cannot maintain employment?” the State Department communication asks.

Currently, immigrant applicants must undergo a medical examination conducted by a doctor approved by the U.S. embassy. The screening includes tests for infectious diseases, an evaluation of mental health history, substance use, and proof of vaccination against illnesses such as measles, polio, and hepatitis B.

However, immigration lawyer Sophia Genovese from Georgetown University noted that the new guidance expands these requirements by directing officials to weigh long-term health conditions, not just communicable diseases, when reviewing visa applications.

End of Article

Fact Check: Did Novo Nordisk Executive Faint In Oval Office? Here's What Actually Happened

Updated Nov 7, 2025 | 12:51 PM IST

SummaryDuring Trump’s Oval Office announcement on TrumpRx, a man fainted, prompting Dr Mehmet Oz to assist him. Many believed the person was Novo Nordisk executive Gordon Findlay, but the company clarified he was not present. The incident renewed attention on how to respond when someone collapses, including CPR steps and safety checks.
Fact Check: Did Novo Nordisk Executive Faint In Oval Office? Here's What Actually Happened

Credits: X

While TrumpRx is making headlines for lowering the prices of popular weight loss drugs, something else has also grabbed attention of many. A video from the Oval Office from the Thursday Press Conference when President Donald Trump was announcing the deal with the drugmakers, a man had collapsed. Many claimed that the person who collapsed was Gordon Findlay, who is Novo Nordisk's executive. Dr Mehmet Oz, an American present and a physician was swift to check on the man who had collapsed. Independent journalist Eric Daugherty shared the video and wrote: "A man just passed out during President Trump's Oval Office announcement. Dr Oz Sprung into action and assisted him. Pray for him."

Also Read: TrumpRx: Will Trump’s New Website Make Prescription Drugs More Affordable?

Is The Man Gordon Findlay?

The reason why many have identified the man as Gordon Findlay because in the video, David Ricks, CEO of Eli Lily could be heard asking, "You okay? Gordon, you okay?" Upon this, the White House Press Secretary Karoline Leavitt said in the statement that "a representative with one of the companies fainted". However, no names were given.

Also Read: TrumpRx Lowered Prices Of Popular Weight Loss Drugs; What More Does Trump's New Medical Website Offer?

Novo Nordisk later clarified the claims, and in a statement to Newsweek, the company said, "Please be aware that CEO Mike Doustdar and EVP, US operations, Dave More were the only two Novo Nordisk representatives in the Oval Office."

Dr Oz had previously also helped out at the Oval office in April, when a child fainted while he was being sworn in. A woman, who many media outlets claimed, appeared to be Oz's daughter, Daphne, escorted the girl who had fainted. Later, the White House official confirmed to Fox News Digital that the girl was family member of Oz and had recovered.

What To Do When Someone Collapses?

If someone collapses in front of you, the first need is for someone to try simple CPR or cardiopulmonary resuscitation, while medical help is on its way. What must one keep in mind if someone collapses?

Check for any danger around the person, and give the shoulders of the person who collapsed a shake. Ask them if they can hear you, notes BBC.

If there is no response, tilt their head back to ensure that the airway is clear. This may be enough for the person to again start breathing.

If they are not breathing, this is when CPR becomes important.

Also Read: Trump Strikes Agreement To Cut Costs of Popular Weight Loss Drugs: All You Need to Know

How To Do CPR The Right Way?

As per NHS, UK, there are two correct ways to practice CPR on adults:

Hands-only CPR

This is to be carry out as a chest compression

  • Start with kneeling next to the person and place the heel of your hand on the breastbone at the centre of their chest. Place the palm of your other hand on top of the hand that is on their chest and interlock your fingers.
  • Position yourself so your shoulders are directly above your hands.
  • Using your body weight (not just your arms), press straight down by 5 to 6cm (2 to 2.5 inches) on their chest.
  • Keeping your hands on their chest, release the compression and allow their chest to return to its original position.
  • Repeat these compressions at a rate of 100 to 120 times a minute until an ambulance arrives or for as long as you can.

CPR with rescue breaths

  • Place the heel of your hand on the center of the person's chest, then place the palm of your other hand on top and press down by 5 to 6cm (2 to 2.5 inches) at a steady rate of 100 to 120 compressions a minute.
  • After every 30 chest compressions, give 2 rescue breaths.
  • Tilt the person's head gently and lift the chin up with 2 fingers. Pinch the person's nose. Seal your mouth over their mouth and blow steadily and firmly into their mouth for about 1 second. Check that their chest rises. Give 2 rescue breaths.
  • Continue with cycles of 30 chest compressions and 2 rescue breaths until they begin to recover or emergency help arrives.

End of Article